Affiliation:
1. Institute of Pharmaceutical Research, GLA University, Mathura-281406, U.P., India
2. School of Pharmaceutical
Sciences, MVN University, Palwal-121105, Haryana, India
Abstract
Abstract:
Nuclear factor erythroid-2-related factor 2 (Nrf2), an inducible transcription factor in
phase II metabolic reactions, as well as xenobiotic response pathway, is referred to as ‘master
regulator’ in anti-oxidant, anti-inflammatory, and xenobiotic detoxification processes. The activity
of Nrf2 is tightly regulated by KEAP1, which promotes ubiquitination, followed by degradation
under homeostatic conditions and also allows Nrf2 to escape ubiquitination, accumulate within the
cell, and translocate in the nucleus upon exposure to the stresses. The Nrf2 pathway has shown an
intrinsic mechanism of defense against oxidative stress (OS). It emerged as a promising therapeutic
target as both inducers and as there is an increasing number of evidence for the protective role of the
Nrf2-ARE pathway towards exacerbations of ROS generation as well as OS, mitochondrial
dysfunction as well as prolonged neuroinflammation is a prevalent pathophysiological process
rooted in brain-related disorders. Elevated concentrations of ROS generation and OS have been
linked to the pathophysiology of a diverse array of brain related disorders, including Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, Friedrich’s ataxia, multiple sclerosis, and
epilepsy. Further, it not only modulates the articulation of anti-oxidant genes but has often been
associated with implicating anti-inflammatory consequences as well as regulating mitochondrial
functionalities and biogenesis. Therefore, Nrf2 can be considered a potential therapeutic target for
the regimen of various brain-related disorders.
Publisher
Bentham Science Publishers Ltd.
Subject
Biochemistry,General Medicine,Structural Biology